Harpoon Therapeutics Inc (NASDAQ:HARP) Receives $23.75 Consensus Price Target from Analysts

Shares of Harpoon Therapeutics Inc (NASDAQ:HARP) have earned an average rating of “Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $23.75.

A number of equities analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Harpoon Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 4th. Citigroup reaffirmed a “buy” rating and issued a $23.00 price target on shares of Harpoon Therapeutics in a research note on Friday, May 24th. Robert W. Baird assumed coverage on shares of Harpoon Therapeutics in a research note on Monday, April 22nd. They issued an “outperform” rating and a $25.00 price target on the stock. Svb Leerink reaffirmed an “outperform” rating on shares of Harpoon Therapeutics in a research note on Tuesday, March 5th. Finally, Wedbush assumed coverage on shares of Harpoon Therapeutics in a research note on Tuesday, March 5th. They issued an “outperform” rating and a $23.00 price target on the stock.

Several large investors have recently modified their holdings of HARP. MPM Asset Management LLC bought a new stake in shares of Harpoon Therapeutics in the first quarter valued at about $42,846,000. New Leaf Venture Partners L.L.C. bought a new stake in shares of Harpoon Therapeutics in the first quarter valued at about $27,666,000. Sphera Funds Management LTD. bought a new stake in shares of Harpoon Therapeutics in the first quarter valued at about $3,133,000. Finally, Fosun International Ltd bought a new stake in shares of Harpoon Therapeutics in the first quarter valued at about $3,062,000. 54.14% of the stock is currently owned by institutional investors.

NASDAQ HARP opened at $12.82 on Tuesday. Harpoon Therapeutics has a 1-year low of $9.07 and a 1-year high of $17.85. The firm has a market capitalization of $293.62 million and a PE ratio of -0.50.

Harpoon Therapeutics (NASDAQ:HARP) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.92) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.47). The firm had revenue of $1.06 million for the quarter, compared to analyst estimates of $1.40 million. Research analysts predict that Harpoon Therapeutics will post -2.78 EPS for the current fiscal year.

About Harpoon Therapeutics

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer.

Featured Story: Buyback For Investors Defined

Analyst Recommendations for Harpoon Therapeutics (NASDAQ:HARP)

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.